Jennison Associates
KPTI icon

Jennison Associates’s Karyopharm Therapeutics KPTI Stock Holding History

Jennison Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,050
Closed -$1.74M – 674
2021
Q4 		$1.74M Buy
18,050
+44
+0.2% +$4.38K ﹤0.01% 551
2021
Q3 		$1.57M Buy
18,006
+9,057
+101% +$940K ﹤0.01% 563
2021
Q2 		$1.39M Buy
8,949
+3,190
+55% +$463K ﹤0.01% 595
2021
Q1 		$909K Buy
+5,759
New +$1.21M ﹤0.01% 635

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Jennison Associates's KPTI Position: Q1 2022 in Review

Jennison Associates sold out of Karyopharm Therapeutics (KPTI) in Q1 2022, closing a stake of 18,050 shares — an estimated $1.74M sold.

Jennison Associates first reported a position in KPTI in Q1 2021 and held it in 4 quarters. The position peaked at $1.74M in Q4 2021. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Jennison Associates reported no remaining Karyopharm Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 18,050 Karyopharm Therapeutics shares in Q1 2022, an estimated $1.74M.
  • Jennison Associates first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 4 quarters.
  • Jennison Associates's Karyopharm Therapeutics position peaked at $1.74M in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.